Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
2.200
-0.050 (-2.22%)
At close: Jun 27, 2025, 4:00 PM
2.229
+0.029 (1.32%)
After-hours: Jun 27, 2025, 7:54 PM EDT
Atai Life Sciences Revenue
Atai Life Sciences had revenue of $1.56M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $1.86M, up 572.56% year-over-year. In the year 2024, Atai Life Sciences had annual revenue of $308.00K, down -1.91%.
Revenue (ttm)
$1.86M
Revenue Growth
+572.56%
P/S Ratio
205.76
Revenue / Employee
$34,500
Employees
54
Market Cap
441.66M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ATAI News
- 26 days ago - atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies - GlobeNewsWire
- 4 weeks ago - atai Life Sciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression - GlobeNewsWire
- 6 weeks ago - atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 6 weeks ago - atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder - GlobeNewsWire
- 3 months ago - atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression - GlobeNewsWire
- 4 months ago - Atai: Following The Path That Spravato Laid And Moving Beyond It - Seeking Alpha
- 4 months ago - atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire